13856 research outputs found
Sort by
复频超音波相位数组驱动系统
No full text[[abstract]]一种用于超音波治疗患者之装置，包含：一超音波数组，其具有复数换能器阵元；一驱动模块，用以驱动该换能器阵元；以及一控制中枢，用以使该驱动模块在两个不同的频率下驱动该换能器阵元
[[alternative]]A smart mosquito trap for capturing different types of mosquitoes into different places and the method thereof
No full text[[abstract]]本發明揭露一種用以將兩種或更多種蚊蟲捕捉至不同倉室中之捕蚊裝置。該捕蚊裝置包含蚊蟲辨識系統及捕捉機構，該蚊蟲辨識系統捕捉蚊蟲之影像資料並辨識蚊蟲之種類，該捕捉機構依據該蚊蟲辨識系統之判定結果，將蚊蟲捕捉至不同倉室中。本發明得以捕捉活體蚊蟲並將其區分為不同種類；此外，記錄的環境數值還能供進一步研究
Methods for detecting hepatitis B virus surface gene non-sense mutations
No full text[[abstract]]A method for in vitro detection of the presence of a C-terminal truncation mutation of a hepatitis B virus (HBV) surface (S) gene encoding a small S protein in an isolated nucleic acid sample is disclosed. An in vitro diagnostic kit for use in the aforementioned method is also disclosed
制备用于以体外转译的方法体外测B型肝炎病毒相关的肝癌变的试剂的用途与体外诊断套组
No full text[[abstract]]本发明揭示一种于体外侦测一分离出的核苷酸检体具有一B型肝炎病毒表面抗原基因C端截断突变的方法。本发明亦揭示利用上述方法的体外诊断套组
Method and composition for treating hepatocellular carcinoma without viral infection by controlling the lipid homeostasis
No full text[[abstract]]The present invention relates to a method and a pharmaceutical composition for treating an HCC negative for HBV/HCV, comprising administering a subject in need thereof an therapeutically effective amount of an inhibitory agent to control the genetic alteration of lipid homeostasis associated genes, including CD36 amplification and ABCG4 deletion. According to the present invention, medicines targeting the lipid metabolism pathways are developed to treat HCC patients with CD36 amplification and/or ABCG4 deletion
[[alternative]]Anti-abeta antibodies and uses thereof
No full text[[abstract]]一種分離的抗體，其結構包含：一輕鏈CDR1(L-CDR1)，具有SEQ ID NO：1序列、SEQ ID NO：7序列、或SEQ ID NO：14序列；一輕鏈CDR2(L-CDR2)，具有SEQ ID NO：2序列或SEQ ID NO：15序列；一輕鏈CDR3(L-CDR3)，具有SEQ ID NO：3序列、SEQ ID NO：8序列、SEQ ID NO：21序列、或SEQ ID NO：24序列；一重鏈CDR1(H-CDR1)，具有SEQ ID NO：4序列、SEQ ID NO：9序列、SEQ ID NO：11序列、SEQ ID NO：16序列、或SEQ ID NO：25序列；一重鏈CDR2(H-CDR2)，具有SEQ ID NO：5序列、SEQ ID NO：12序列、SEQ ID NO：17序列、SEQ ID NO：19序列、SEQ ID NO：22序列、或SEQ ID NO：26序列；以及一重鏈CDR3(H-CDR3)，具有SEQ ID NO：6序列、SEQ ID NO：10序列、SEQ ID NO：13序列、SEQ ID NO：18序列、SEQ ID NO：20序列、SEQ ID NO：23序列、或SEQ ID NO：27序列；其中該抗體對Aβ1-42或一N端修飾型Aβ1-42皆具有特異性結合能力
抗Aベータ抗体及びその使用
No full text[[abstract]]An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to Aβ1-42 or an N-terminal modified form thereof
Pyrazole compounds
No full text[[abstract]]Disclosed are pyrazole compounds, encompassed by formula (I) shown in the Specification, useful for treating peripheral cannabinoid 1 receptor mediated disorders. Also disclosed are pharmaceutical compositions and methods related to use of these compounds
吡唑類化合物
No full text[[abstract]]本發明公開了如化學式(I)所示的吡唑類化合物，其可用於治療周邊大麻素1受體介導的疾病，此外，本發明亦公開了關於該些化合物的醫藥組合物以及使用方法
吡唑類化合物
No full text[[abstract]]本发明公开了如化学式 (I) 所示的吡唑类化合物，其可用于治疗周边大麻素 1 受体介导的疾病，此外，本发明亦公开了关于该些化合物的医药组合物以及使用方法